Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

• CLINICAL_TRIALS trial_result · 2016-02-24
  Clinical Trial Update: Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients [Phase 4]

  This entry describes a Phase 4 clinical trial evaluating a low-dose chemotherapy regimen combined with a tyrosine kinase inhibitor to treat …

• CLINICAL_TRIALS trial_result · 2016-01-22
  Clinical Trial Update: Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [Phase 2]

  This clinical trial update reports long-term safety data for dasatinib in patients with chronic myeloid leukemia and Philadelphia chromosome…

• CLINICAL_TRIALS withdrawal · 2015-10-30
  Clinical Trial Update: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia [Phase 2]

  A Phase 2 study evaluating Nilotinib with combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic …

• FDA approval · 2015-10-15
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Tasigna (nilotinib) submitted by Novartis Pharmaceuticals Corporation. The approval pertains to …

• CLINICAL_TRIALS trial_result · 2015-09-18
  Clinical Trial Update: Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia [Phase 2]

  A Phase 2 study evaluating Hyper-CVAD plus Imatinib Mesylate for Philadelphia chromosome-positive acute lymphoblastic leukemia; results were…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2015-08-21
  Clinical Trial Update: Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia [Phase 1]

  Clinical trial update for XL228 in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia; the Phase 1 s…

• CLINICAL_TRIALS trial_result · 2015-05-29
  Clinical Trial Update: First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL [Phase 2]

  Phase 2 trial evaluating first-line dasatinib in combination with conventional chemotherapy for adults with Philadelphia chromosome-positive…

• FDA approval · 2015-04-23
  FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

  FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) submitted by Takeda Pharmaceuticals America, Inc., under NDA 2…

• CLINICAL_TRIALS trial_result · 2015-01-30
  Clinical Trial Update: A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) [Phase 1]

  A Phase I dose-escalation combination study in patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblast…

• FDA approval · 2015-01-26
  FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)

  FDA approved a supplemental application for dasatinib by Prasco Laboratories, enabling the marketing of a generic version. The drug is indic…

• CLINICAL_TRIALS trial_result · 2015-01-26
  Clinical Trial Update: A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008) [Phase 2]

  Phase II trial of MK0457 in T315I-mutant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia was term…

• CLINICAL_TRIALS trial_result · 2014-10-22
  Clinical Trial Update: Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML [Phase 3]

  This is a Phase 3 clinical trial update for dasatinib (BMS-354825) in chronic myeloid leukemia; the study is completed and results were post…

• FDA approval · 2014-09-25
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Tasigna (nilotinib) submitted by Novartis Pharmaceuticals Corporation.

• CLINICAL_TRIALS trial_result · 2014-04-10
  Clinical Trial Update: Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia [Phase 1]

  Phase 1 trial evaluating induction therapy with cytarabine, high-dose mitoxantrone, and dasatinib for Philadelphia chromosome-positive acute…

• CLINICAL_TRIALS research · 2014-01-13
  Clinical Trial Update: Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)

  Clinical trial update on the AMICA study examining patterns of ABL mutations in Asian patients with imatinib-resistant chronic myeloid leuke…

• FDA approval · 2013-08-14
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Tasigna (nilotinib) from Novartis Pharmaceuticals Corporation. The approval updates the labeling…

• CLINICAL_TRIALS trial_result · 2013-06-05
  Clinical Trial Update: Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

  A completed Phase 1/2 trial evaluated arsenic trioxide in combination with imatinib mesylate for patients with accelerated-phase or blast-ph…

• FDA approval · 2013-05-22
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Tasigna (nilotinib) to update the product labeling.

• CLINICAL_TRIALS trial_result · 2012-03-13
  Clinical Trial Update: Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. [Phase 1]

  A pediatric pharmacokinetic study of Glivec/Gleevec (imatinib) in children aged 1 to less than 4 with chronic myeloid leukemia, Philadelphia…

• CLINICAL_TRIALS trial_result · 2011-10-05
  Clinical Trial Update: Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive [Phase 2]

  Phase 2 trial evaluating imatinib mesylate in combination with vincristine and dexamethasone for Philadelphia chromosome-positive acute lymp…

• CLINICAL_TRIALS trial_result · 2011-04-19
  Clinical Trial Update: Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study [Phase 1]

  Phase 1 trial conducted by Bristol-Myers Squibb in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemi…

• FDA approval · 2011-01-14
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for Tasigna (nilotinib) by Novartis Pharmaceuticals to modify labeling and/or expand its approved in…

• CLINICAL_TRIALS trial_result · 2010-12-14
  Clinical Trial Update: Rollover Study of BMS-354825 in Patients With CML and Ph+ALL [Phase 1, Phase 2]

  Rollover study of BMS-354825 (dasatinib) in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblas…

• FDA approval · 2010-10-28
  FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)

  FDA approved a supplemental application for dasatinib filed by Prasco Laboratories.

• FDA approval · 2010-03-15
  FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for Tasigna (nilotinib) filed by Novartis Pharmaceuticals Corporation. The approval updates the …